GNLX:NASDAQ
Genelux Corp
$2.52
arrow_downward
-0.79%(-0.020) 1D
Oct 7, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
$2.52
High
$2.59
Low
$2.46
Mkt. cap
114.02M
Avg. vol.
270.21K
Volume
550.98K
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.59
Shares outstanding
45.24M
No. of employees
26
Open
$2.52
High
$2.59
Low
$2.46
Mkt. cap
114.02M
Avg. vol.
270.21K
Volume
550.98K
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.59
Shares outstanding
45.24M
No. of employees
26
News stories
From web sources and news partners
Simply Wall Street
·
29 minutes ago
Powell Industries (POWL) Could Be 41% Undervalued As LNG And Data Center Demand Builds
MarketBeat
·
27 minutes ago
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in Stock
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitegenelux.com